Back to News
Market Impact: 0.12
Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners
Source: PR Newswire
Company FundamentalsPatents & Intellectual PropertyM&A & RestructuringPrivate Markets & Venture
Haisco Pharmaceutical Group (002653) announced on Aug. 25 that it entered an exclusive licensing agreement with Sentivera, a new US venture backed by Population Health Partners and ARCH Venture. The news does not provide deal economics (e.g., upfront, milestone amounts, or royalties), limiting near-term clarity on financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
More News
- ‘How many canaries have we killed in the coal mine?’ — Wall Street debates if the latest AI bubble warnings are another head fake or the real thing
- Ericsson’s organic sales rise 7% as it merges its two Asian units
- Bending Spoons wants to revive software castoffs. Berkshire is backing the plan
- TSMC posts a sixth straight record profit but turns cautious on 2027
- Alphabet’s chief investment officer responds to Jefferies warning that the most likely outcome of the AI boom is massive U.S. capital destruction
- SpaceX’s ambitious, expensive gamble to replace AT&T, T-Mobile, and Verizon